US-based generic pharmaceutical firm Hospira Inc, which had acquired Orchid Chemicals and Pharmaceuticals Ltd’s generic injectables business in 2010, is in the process of infusing $275-$325 million (around Rs 1,300-1,600 crore) towards capacity expansion in India.
It has also initiated plans to qualify and validate manufacturing and related activities for certain oncology compounds in its joint venture with Ahmedabad-based Cadila Healthcare Ltd.